ZyVersa Therapeutics (NASDAQ:ZVSA) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of ZyVersa Therapeutics (NASDAQ:ZVSA) in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock. HC Wainwright also issued estimates for ZyVersa Therapeutics’ Q2 2024 earnings at ($0.52) EPS, FY2025 earnings at ($4.61) EPS, FY2026 earnings at ($6.58) EPS, FY2027 earnings at ($8.89) EPS and FY2028 earnings at ($11.17) EPS.

ZyVersa Therapeutics Price Performance

Shares of ZVSA stock opened at $0.75 on Tuesday. The company’s fifty day simple moving average is $0.74 and its 200-day simple moving average is $2.09. ZyVersa Therapeutics has a 52 week low of $0.50 and a 52 week high of $90.65.

Hedge Funds Weigh In On ZyVersa Therapeutics

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Walleye Capital LLC purchased a new stake in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 980,568 shares of the company’s stock, valued at approximately $128,000. Walleye Capital LLC owned approximately 3.17% of ZyVersa Therapeutics at the end of the most recent quarter. 3.91% of the stock is currently owned by institutional investors.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.